Almost half of children given weight-loss jab semaglutide lost enough weight to no longer be considered clinically obese, a study found.
The study, presented at the European Congress on Obesity in Dublin, is the latest in a series of trials showing the jab offers life-saving treatment to people with obesity.
Two hundred and one adolescents with clinical obesity between 12 and 18 were entered in a trial to test the effect of the weight-loss drug semaglutide, marketed under the name Ozempic when it is prescribed for diabetes and Wegovy when prescribed for weight loss.
One hundred and thirty-four of these children received a weekly dose of 2.4 milligrams of semaglutide for more than a year, alongside healthy lifestyle counseling, The Guardian reported. The rest received the same lifestyle counseling and a placebo jab.
The study found that at the end of 68 weeks of treatment, almost 45% of children who got semaglutide dropped enough weight to no longer be considered clinically obese, compared to just 12% of adolescents who received the placebo, per The Guardian.
The results are "historically unprecedented with treatments other than bariatric surgery," Aaron Kelly, a study lead and the co-director of the Center...
Park Filed Complaint Against President Lee Ahead of 2021 Election Jang Youngha Sentenced to One Year in Prison, Two Years Probation Confirmed The police have launched an investigation into Park Chu...